The mixed bullish ratings from analysts indicate a positive outlook for Travere Therapeutics. The average price target of $27.78 suggests an upside potential from the current price of $18.155. However, the decrease in the average price target from the previous average of $35.43 indicates a slightly less optimistic view compared to the past. This analysis is based on the ratings and price targets provided by the 9 analysts.